LitCovid-sample-Enju  

PMC:7228307 / 59886-60294 JSONTXT 10 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T393 0-7 JJ denotes Further
T394 8-21 NN denotes understanding
T395 22-24 IN denotes of
T396 25-28 WRB denotes how
T397 29-37 NN denotes antibody
T398 38-47 NN denotes structure
T399 48-55 VBZ denotes affects
T400 56-60 NN denotes FcγR
T401 61-69 NN denotes function
T402 70-72 VBZ denotes is
T403 73-82 JJ denotes essential
T404 83-86 IN denotes for
T405 87-93 JJ denotes future
T406 94-105 NN denotes development
T407 106-108 IN denotes of
T408 109-113 RBR denotes more
T409 114-120 JJ denotes potent
T410 121-124 CC denotes and
T411 125-134 JJ denotes effective
T412 135-139 NNS denotes mAbs
T413 141-148 RB denotes Already
T414 148-149 -COMMA- denotes ,
T415 150-161 NN denotes engineering
T416 162-164 IN denotes of
T417 165-168 DT denotes the
T418 169-172 NN denotes IgG
T419 173-175 NN denotes Fc
T420 176-179 CC denotes and
T421 180-183 PRP-DOLLAR- denotes its
T422 184-190 NN denotes glycan
T423 191-194 VBZ denotes has
T424 195-201 VBN denotes proved
T425 202-203 DT denotes a
T426 204-210 JJ denotes potent
T427 211-214 CC denotes and
T428 215-224 JJ denotes effective
T429 225-233 NN denotes approach
T430 234-237 IN denotes for
T431 238-248 VBG denotes increasing
T432 249-252 DT denotes the
T433 253-261 JJ denotes clinical
T434 262-275 NN denotes effectiveness
T435 275-276 -COMMA- denotes ,
T436 277-287 JJ denotes functional
T437 288-299 NN denotes specificity
T438 300-303 CC denotes and
T439 304-310 NN denotes safety
T440 311-313 IN denotes of
T441 314-325 JJ denotes therapeutic
T442 326-330 NNS denotes mAbs
T443 331-334 CC denotes and
T444 335-337 VBZ denotes is
T445 338-340 DT denotes an
T446 341-349 VBG denotes emerging
T447 350-357 NN denotes pathway
T448 358-360 TO denotes to
T449 361-364 DT denotes the
T450 365-376 NN denotes development
T451 377-379 IN denotes of
T452 380-383 DT denotes the
T453 384-394 NN denotes “next‐gen”
T454 395-407 NNS denotes therapeutics
R402 T394 T393 arg1Of understanding,Further
R403 T394 T395 arg1Of understanding,of
R404 T396 T395 arg2Of how,of
R405 T399 T396 arg1Of affects,how
R406 T398 T397 arg1Of structure,antibody
R407 T398 T399 arg1Of structure,affects
R408 T401 T399 arg2Of function,affects
R409 T401 T400 arg1Of function,FcγR
R410 T394 T402 arg1Of understanding,is
R411 T403 T402 arg2Of essential,is
R412 T394 T403 arg1Of understanding,essential
R413 T403 T404 arg1Of essential,for
R414 T406 T404 arg2Of development,for
R415 T406 T405 arg1Of development,future
R416 T406 T407 arg1Of development,of
R417 T412 T407 arg2Of mAbs,of
R418 T412 T408 arg1Of mAbs,more
R419 T412 T409 arg1Of mAbs,potent
R420 T409 T410 arg1Of potent,and
R421 T411 T410 arg2Of effective,and
R422 T412 T411 arg1Of mAbs,effective
R423 T443 T413 arg1Of and,Already
R424 T443 T414 arg1Of and,","
R425 T415 T416 arg1Of engineering,of
R426 T420 T416 arg2Of and,of
R427 T419 T417 arg1Of Fc,the
R428 T419 T418 arg1Of Fc,IgG
R429 T419 T420 arg1Of Fc,and
R430 T422 T420 arg2Of glycan,and
R431 T422 T421 arg1Of glycan,its
R432 T415 T423 arg1Of engineering,has
R433 T424 T423 arg2Of proved,has
R434 T415 T424 arg1Of engineering,proved
R435 T435 T424 arg2Of ",",proved
R436 T429 T425 arg1Of approach,a
R437 T429 T426 arg1Of approach,potent
R438 T426 T427 arg1Of potent,and
R439 T428 T427 arg2Of effective,and
R440 T429 T428 arg1Of approach,effective
R441 T429 T430 arg1Of approach,for
R442 T431 T430 arg2Of increasing,for
R443 T434 T431 arg2Of effectiveness,increasing
R444 T434 T432 arg1Of effectiveness,the
R445 T434 T433 arg1Of effectiveness,clinical
R446 T429 T435 arg1Of approach,","
R447 T438 T435 arg2Of and,","
R448 T438 T436 arg1Of and,functional
R449 T437 T438 arg1Of specificity,and
R450 T439 T438 arg2Of safety,and
R451 T438 T440 arg1Of and,of
R452 T442 T440 arg2Of mAbs,of
R453 T442 T441 arg1Of mAbs,therapeutic
R454 T424 T443 arg1Of proved,and
R455 T444 T443 arg2Of is,and
R456 T415 T444 arg1Of engineering,is
R457 T447 T444 arg2Of pathway,is
R458 T447 T445 arg1Of pathway,an
R459 T447 T446 arg1Of pathway,emerging
R460 T447 T448 arg1Of pathway,to
R461 T450 T448 arg2Of development,to
R462 T450 T449 arg1Of development,the
R463 T450 T451 arg1Of development,of
R464 T454 T451 arg2Of therapeutics,of
R465 T454 T452 arg1Of therapeutics,the
R466 T454 T453 arg1Of therapeutics,“next‐gen”